Wuhan Historical Cash Flow
| 300871 Stock | 12.12 0.29 2.45% |
Analysis of Wuhan Hvsen cash flow over time is an excellent tool to project Wuhan Hvsen Biotechnology future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 227.9 M or Total Cash From Operating Activities of 90.8 M as it is a great indicator of Wuhan Hvsen ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Wuhan Hvsen Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Wuhan Hvsen Biotechnology is a good buy for the upcoming year.
Wuhan |
About Wuhan Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Wuhan balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Wuhan's non-liquid assets can be easily converted into cash.
Wuhan Hvsen Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from Wuhan Hvsen's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Wuhan Hvsen Biotechnology current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Wuhan Hvsen Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Wuhan Hvsen's Net Borrowings is projected to increase significantly based on the last few years of reporting. The current year's Capital Expenditures is expected to grow to about 227.9 M, whereas Total Cashflows From Investing Activities is projected to grow to (640.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 5.3M | 6.9M | 28.8M | 30.3M | Depreciation | 28.5M | 61.9M | 120.4M | 126.4M |
Wuhan Hvsen cash flow statement Correlations
Click cells to compare fundamentals
Wuhan Hvsen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Wuhan Hvsen cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Borrowings | 40.2M | (16.6M) | 61.7M | 81.6M | 93.8M | 98.5M | |
| Total Cashflows From Investing Activities | (122.9M) | (670.4M) | (185.1M) | (749.5M) | (674.6M) | (640.9M) | |
| Capital Expenditures | 123.1M | 230.8M | 600.1M | 428.9M | 184.3M | 227.9M | |
| Total Cash From Operating Activities | 105.2M | 48.3M | 155.7M | 96.7M | 92.9M | 90.8M | |
| Change To Operating Activities | 21.1M | 1.2M | 18.3M | (937.4K) | (1.1M) | (1.0M) | |
| End Period Cash Flow | 81.9M | 285.5M | 966.1M | 278.6M | 229.5M | 274.2M | |
| Change To Netincome | 5.0M | 8.3M | (5.1M) | 13.3M | 15.3M | 16.1M | |
| Change To Liabilities | 26.0M | 120.5M | 65.3M | (76.0M) | (68.4M) | (64.9M) | |
| Change To Inventory | 8.8M | (55.8M) | (105.9M) | 30.4M | (28.1M) | (29.5M) | |
| Change In Cash | 4.2M | 203.6M | 680.6M | (687.5M) | (49.1M) | (46.6M) | |
| Free Cash Flow | (17.8M) | (182.5M) | (444.4M) | (332.2M) | (91.4M) | (96.0M) | |
| Change In Working Capital | 3.8M | (131.2M) | (18.9M) | (31.1M) | (76.2M) | (80.0M) | |
| Begin Period Cash Flow | 77.7M | 81.9M | 285.5M | 966.1M | 278.6M | 277.3M | |
| Depreciation | 12.1M | 19.1M | 28.5M | 61.9M | 120.4M | 126.4M | |
| Other Non Cash Items | 1.8M | 2.5M | 5.3M | 6.9M | 28.8M | 30.3M | |
| Dividends Paid | 16.7M | 6.0M | 47.9M | 62.5M | 58.6M | 37.4M | |
| Change To Account Receivables | (37.2M) | (195.0M) | 21.7M | 14.4M | 16.6M | 17.4M | |
| Net Income | 68.8M | 150.2M | 132.9M | 52.7M | 16.8M | 15.9M | |
| Total Cash From Financing Activities | 21.9M | 825.7M | 710.1M | (34.6M) | (39.8M) | (37.8M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Wuhan Stock
The Cash Flow Statement is a financial statement that shows how changes in Wuhan balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Wuhan's non-liquid assets can be easily converted into cash.